Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced XXXX .

@entity1 @entity135 @entity137 @entity308 @entity2133 @entity900 @entity33 @entity1487
The aim of this study was to review our experience with a treatment regimen that combined conventionally fractionated radiation therapy (70 Gy over 7 weeks) with chemotherapy ( @entity900 and @entity1487 ), given concurrently in the last 2 weeks of radiation therapy in @entity1 with previously untreated advanced @entity135 region.Twenty-eight @entity1 , all but two having UICC stage IV disease, were treated at the Peter MacCallum Cancer Institute between November 1995 and April 1998. Planned chemotherapy consisted initially of continuous infusion at 10 mg/m(2) per day of @entity900 and 400 mg/m(2) per day of @entity1487 on days 1-5 of weeks 6 and 7 of a conventionally fractionated course of radiotherapy. After the first 14 @entity1 , the dose of @entity1487 was reduced to 360 mg/m(2) per day because of acute @entity137 .36.8 months), with an estimated 50% surviving at 2 years (CI, 29-71%). Sixteen @entity1 (57%) developed confluent @entity33 and 11 (39%) developed @entity33 . The median duration of @entity33 for these 27 @entity1 was 1.5 months. Seventeen @entity1 (61%) required nutritional support for a median duration of 1.4 months. Fourteen @entity1 (50%) had grade three skin reactions, and 12 (43%) had one or more other significant (Grade 3) @entity137 , predominantly infective. Grade 3 late @entity137 has been observed in three @entity1 to date (three @entity2133 , including one with severe @entity308 ), and one @entity1 had chronic ulceration of the oral tongue (grade 4). This chemoradiation regimen achieved an excellent complete response rate and good locoregional control at 2 years in @entity1 with a poor initial prognosis. Acute @entity137 was significant but manageable. The regimen offers an alternative to surgery and postoperative radiation therapy in locally advanced @entity135 .
